Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
Location: South Korea
Employees: 51-200
Total raised: $128.76M
Founded date: 2011
Investors 4
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
| - | Brisbane A... | brisbanean... |
| - | First Ligh... | firstlight... |
| - | OneVenture... | one-ventur... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 28.08.2025 | Series D | $58.75M | SPRIM Vent... |
| 08.12.2022 | - | $23M | - |
| 05.10.2020 | - | $22.01M | - |
| 18.03.2020 | Grant | $5M | - |
| 10.02.2015 | Series B | $20M | - |
Mentions in press and media 25
| Date | Title | Description |
| 26.02.2026 | SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union | SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines in Europe to improve vaccine performance and access. Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and... |
| 28.08.2025 | Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery Technology | Vaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a... |
| 18.03.2025 | Vaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology | BRISBANE, Australia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the United States patent office covering proprietary manufacturing technology for it... |
| 18.02.2025 | Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery | BRISBANE, Australia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company, today announced it has completed enrollment for its Phase I clinical trial of a vaccine against an avian influenza A (H7N9) virus wit... |
| 14.01.2025 | Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination | January xx, 2025 – BRISBANE, Australia & CAMBRIDGE, Mass. – Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a Concept Stage Winner of the... |
| 06.06.2023 | Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ p... |
| 19.01.2023 | Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access | CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-fr... |
| 06.12.2022 | Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced it has completed a financing round which raised US$23 million (A$34 million) in new funds. This investment round was led by existin... |
| 05.12.2022 | Vaxxas Raises US$23M in Funding | Vaxxas, a Cambridge, MA- and Brisbane, Australia-based clinical-stage biotechnology company, raised US$23M in funding. The round was led by OneVentures and UniQuest Pty Ltd. This US$23M in new funding will leverage non-dilutive financial su... |
| 05.12.2022 | Vaxxas Raises $23M for Needle-Free Vaccine Tech Jobs at Vaxxas | Vaxxas’ needle-free vaccine patch. | Photo: Vaxxas / LinkedIn Trypanophobia, the fear of needles and medical injections, impacts 10 percent of adults, according to the Cleveland Clinic. This fear makes it hard for some people to get vaccine... |
Show more